- Home
- KOSS vs CGTX Comparison
KOSS vs CGTX Comparison
Compare KOSS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOSS
- CGTX
- Stock Information
- Founded
- KOSS 1953
- CGTX 2007
- Country
- KOSS United States
- CGTX United States
- Employees
- KOSS N/A
- CGTX N/A
- Industry
- KOSS Consumer Electronics/Appliances
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- KOSS Consumer Staples
- CGTX Health Care
- Exchange
- KOSS Nasdaq
- CGTX Nasdaq
- Market Cap
- KOSS 49.1M
- CGTX 158.8M
- IPO Year
- KOSS N/A
- CGTX 2021
- Fundamental
- Price
- KOSS $5.05
- CGTX $1.67
- Analyst Decision
- KOSS
- CGTX Strong Buy
- Analyst Count
- KOSS 0
- CGTX 3
- Target Price
- KOSS N/A
- CGTX $2.83
- AVG Volume (30 Days)
- KOSS 58.4K
- CGTX 1.9M
- Earning Date
- KOSS 10-28-2025
- CGTX 11-12-2025
- Dividend Yield
- KOSS N/A
- CGTX N/A
- EPS Growth
- KOSS N/A
- CGTX N/A
- EPS
- KOSS N/A
- CGTX N/A
- Revenue
- KOSS $12,624,170.00
- CGTX N/A
- Revenue This Year
- KOSS N/A
- CGTX N/A
- Revenue Next Year
- KOSS N/A
- CGTX N/A
- P/E Ratio
- KOSS N/A
- CGTX N/A
- Revenue Growth
- KOSS 2.93
- CGTX N/A
- 52 Week Low
- KOSS $4.00
- CGTX $0.22
- 52 Week High
- KOSS $8.59
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- KOSS 45.66
- CGTX 48.63
- Support Level
- KOSS $5.04
- CGTX $1.66
- Resistance Level
- KOSS $5.30
- CGTX $1.78
- Average True Range (ATR)
- KOSS 0.30
- CGTX 0.15
- MACD
- KOSS 0.03
- CGTX -0.01
- Stochastic Oscillator
- KOSS 33.67
- CGTX 17.39
About KOSS Koss Corporation
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.